The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).
Bristol Myers Squibb announced the Phase III CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis.
ONO Pharma has received manufacturing and marketing approval for the human anti-human PD-1 monoclonal antibody Opdivo Intravenous Infusion 20 mg/100...
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase III study evaluating nivolumab versus dacarbazine (DTIC) (CHECKMATE 066) in...
BMS announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in...
The National Institute for Health and Care Excellence (NICE) in draft guidance has not recommended Opdivo (nivolumab) from BMS as...
NICE,( The National Institute for Health and Care Excellence),has rejected Opdivo (nivolumab) from BMS as a cost effective treatment for...
BMS has announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care...
UK's NICE has recommended that the combination of Opdivo + Yervoy (nivolumab + ipilimumab), from BMS, for the treatment of...
The FDA has expanded the use of Opdivo (nivolumab) from BMS, as a single-agent to include previously untreated BRAF mutation-positive...